About the Report
Gene therapy is an exciting field with promising advancements in editing technologies and research. Scientists and researchers are exploring innovative approaches that could revolutionize the way we treat diseases.
In this report, we analyze 337 assets from the Beacon Gene Therapy database to deliver an in-depth analysis of the editing technologies used in the gene therapy field. We explore the diverse range of diseases being targeted, the mechanisms of action employed, and the distribution of various editing technologies.
Our aim is to provide you with actionable insights that will help you make informed decisions and contribute to the development of transformative therapies.
Beacon Gene Therapy
How the most complete gene therapy database can help you
What we cover
We included trial and drug records for preclinical, active, approved, and discontinued:
- RNA/DNA Viral vector-based therapies
- DNA Non-viral vector-based therapies
- Genetically Modified cell therapies
- Empty Vector Trials
- Other comparable modalities within gene therapy, whether cell-free or cell-based
- Beacon Gene Therapy covers all genetically driven non-oncology indications that utilize gene therapy to mediate the condition.
How Beacon Gene Therapy works
Search the clinical trial and drug landscape by gene/mutation, editing technology (CRISPR/Cas9, Cas-CLOVER, etc.), gene delivery system, promoter, etc., instantaneously and/or extract the data points you need to conduct more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the gene therapy space.
If publicly available, information regarding immunogenicity is included (unique to Beacon Gene Therapy)